Myriad Genetics (MYGN) Short term Debt (2016 - 2025)

Myriad Genetics (MYGN) posted quarterly Short term Debt of $59.4 million for Q2 2025, down 42.94% sequentially from $104.1 million in Q2 2021.

Myriad Genetics (MYGN) Short term Debt (2016 - 2025) Analysis & Trends

Myriad Genetics has disclosed Short term Debt across 7 years of filings, most recently posting $59.4 million for Q2 2025.

In Q2 2025, Short term Debt changed N/A year-over-year to $59.4 million; the TTM figure through Jun 2025 stood at $59.4 million (changed N/A YoY), while the FY2020 annual figure was $3.1 million, down 8.82% from the prior year.
Short term Debt eased to $59.4 million in Q2 2025, from $104.1 million in the prior quarter.
Over the last five years, Short term Debt for MYGN reached as high as $104.1 million in Q2 2021 and fell as low as $59.4 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Waters	31,055.11 Bn	31,054.65 Bn	1.11 Bn
2	Thermo Fisher Scientific	191.02 Bn	187.77 Bn	7.74 Bn
3	Danaher	137.16 Bn	131.47 Bn	3.59 Bn
4	Idexx Laboratories	42.82 Bn	42.62 Bn	722.74 Mn
5	Natera	39.09 Bn	37.99 Bn	696.04 Mn
6	Agilent Technologies	37.61 Bn	35.81 Bn	990.00 Mn
7	Iqvia Holdings	34.23 Bn	32.25 Bn	1.36 Bn
8	Illumina	28.14 Bn	26.98 Bn	721.00 Mn
9	Mettler Toledo International	26.40 Bn	26.33 Bn	555.82 Mn
10	Myriad Genetics	562.20 Mn	437.80 Mn	137.60 Mn

Download Data